Background and Objectives: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. However, its prognosis remains poor. Expression of cluster of differentiation 90 (CD90) has been identified as an indicator of poor prognosis in many cancers. Here, we examined the importance of CD90 expression in ICC.
Moreover, hepatic stem/progenitor cells have been shown to express CD90 during normal fetal and adult liver development and regeneration. 4 ,5 CD90 expression has been reported to be an indicator of poor prognosis in many malignancies, and has various effects in cancer development. [6] [7] [8] For instance, in hepatocellular carcinoma, it is associated with tumor differentiation and metastasis. 9, 10 However, few studies on CD90 expression in ICC have been conducted.
The aims of this study were to clarify the significance of CD90 expression in ICC and examine its clinical utility. We tested CD90 expression in human ICC surgical specimens, and assessed its relationship with clinicopathological findings and prognosis. Moreover, we analyzed the characteristics of CD90 +/− cells, with a particular focus on metastatic potential, using human ICC cell lines to elucidate the role of CD90 and CD90 expression in this malignancy.
| MATERIALS AND METHODS

| Patients
This study included 77 consecutive patients with pathologically confirmed ICC diagnosed from January 2001 to December 2013 at Kyoto University Hospital. The clinicopathological characteristics of the subjects are summarized in Table 1 . The observation period lasted until the patient's death or the end of this study (31 December 2014). Written informed consent for the use of resected tissue samples was obtained from all patients in accordance with the Declaration of Helsinki, and this study was approved by the institutional review committee of our hospital (R0921-1).
| Immunohistochemistry
We utilized thinly cut, paraffin-embedded sections of the surgically resected specimens for immunohistochemical analysis. Once deparaffinized and rehydrated, the sections were heated in Target Retrieval Solution (Dako, Santa Clara, CA) for 8 minutes in a microwave for antigen retrieval. The sections were then incubated in 3% hydrogen peroxide in methanol for 10 minutes, before being exposed to a mouse anti-human CD90 primary antibody (diluted 1:150; BioLegend, San Diego, CA) at 4°C for 16 hours. After thorough rinsing, the sections were incubated for 30 minutes with horseradish peroxidase-conjugated anti-mouse immunoglobulin G (EnVision+ Kit, Dako) and subsequently for 5 minutes with 3,3′-diaminobenzidine substrate (Dako). The cells stained for CD90 were relatively rare even in the positive patients. The CD90-positivity of 5% or more was defined as a positive cut-off value to eliminate results from nonspecific staining. For immunofluorescence staining, sections were incubated in 2% bovine serum albumin for 30 minutes before being exposed to mouse anti-human CD90 and rabbit anti-human α-smooth muscle actin (α-SMA) primary antibodies (Abcam, Cambridge, UK) diluted 1:150 and 1:500, respectively. Alexa Fluor (Molecular Probes, Eugene, OR) 488-conjugated goat anti-mouse and Alexa Fluor 555-conjugated donkey anti-rabbit secondary antibodies (both diluted 1:500) were used to visualize CD90 and α-SMA staining, respectively. The stained tissues were covered with Vectashield mounting medium (Vector Laboratories Inc., Burlingame, CA) containing 4′,6-diamidino-2-phenylindole. The slides were reviewed and scored independently by two investigators (R Yamaoka and T Ishii) who were blinded to the patient's information.
| Cell culture
Three human ICC cell lines were tested in this study. RBE and SSP-25 cells were obtained from the RIKEN Bioresource Center (Tsukuba, Japan) and HuCCT-1 cells were obtained from the Cell Resource Center for Biochemical Research at Tohoku University (Sendai, Japan). All cells were authenticated by short tandem repeat profiling analysis before receipt and were propagated for less than 6 months after resuscitation.
Cells were cultured at 37°C in 5% CO 2 in RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (Gibco, Waltham, MA).
| Flow cytometry and cell sorting
The cultured cells were prepared as described previously. 
| Wound-healing and migration assays
Wound-healing assays were used to assess cell motility. We seeded the 
| CD90 knockdown by RNA interference
We transfected CD90-small interfering RNA (siRNA) (#4427037-s14125 or #4427037-s14126; Invitrogen) or negative control siRNA (#4390843; Invitrogen) at a final concentration of 10 nmol/L into ICC cells, using Lipofectamine LTX (Invitrogen) according to the manufacturer's protocol.
| Assessment of Wnt/β-catenin signaling activation
To evaluate activation of the Wnt/β-catenin signaling pathway in ICC cells, we stained nuclear active β-catenin by immunohistochemistry.
We fixed and stained the cultured cells as previously described. 14, 15 An anti-active β-catenin primary antibody (Merck Millipore, Burling- Mean ± SD of three or more independent experiments are reported.
| Statistical analysis
Postoperative recurrence-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method and analyzed with the log-rank test. Significant variables from the univariate analysis were included in a multivariate analysis using a Cox regression model with forward stepwise selection. P value less than 0.05 was defined as indicating a statistically significant difference.
3 | RESULTS
| CD90 expression in human ICC surgical specimens
To examine CD90 expression in human ICC, 77 surgically resected ICC tumors were subjected to immunohistological assays. The followup period from surgery until death or the end of the study ranged from 0.34 to 11.7 years (median, 2.66 years). CD90 expression was observed in 25 of the 77 patients. In one patient, CD90 + cells were found diffusely distributed within poorly differentiated ICC tissue ( Figure 1A ), whereas in another patient, they were seen maintaining an incomplete luminal structure in the tumor stroma ( Figure 1B ).
Lymph node metastasis was significantly associated with tumor CD90 expression (Table 1) . Furthermore, there were no significant correlations between CD90 expression and the surgical factors (Table 2) . Median RFS and OS were 0.52 and 2.00 years for CD90 + patients and 1.85 and 6.87 years for CD90 − patients, respectively. CD90 + patients exhibited significantly shorter RFS ( Figure 1C ; P < 0.01) and OS ( Figure 1D ; P < 0.01) than CD90 − patients. The log-rank test revealed that CD90 expression, multiple tumors, lymph node metastasis, high serum carbohydrate antigen level, and poorly differentiated tumor were associated with shorter RFS (Table 3) and OS (Table 4 ). Multivariate analysis demonstrated that tumor differentiation, CD90 expression, and CA 19-9 level were independent predictors of postoperative recurrence, and that the latter two were also independent predictors of OS (Table 5 ).
Immunohistochemical analysis was also performed to evaluate expression of CD90 in patients diagnosed with lymph node metastasis. CD90 expression was noted in the metastatic lymph nodes of 12 of the 23 patients in this group ( Figure 1E ). CD90 expression in metastatic lymph nodes was more frequent among patients with CD90 + primary tumors than among those with CD90 − primary tumors ( Figure 1F ; P < 0.01). There were no significant differences in the total number of resected lymph nodes between the CD90 + and CD90 -primary tumors ( Figure 1F ). These results suggest that CD90 expression in ICC is an independent indicator of poor prognosis, and is strongly associated with lymph node metastasis. To show that CD90 was expressed in only tumor cells
and not stromal fibroblasts, we performed double immunofluorescence staining of CD90 and α-SMA, the latter of which is known to Figure 1G ). group. It is reported that the cell lines we used in this study have low tumorigenicity. 30 Therefore, there appear to be some discrepancies between animal models and clinical specimens with respect to CD90 expression in ICC. Second, the role of CD90 was not well defined in the present work. Although CD90 was shown to regulate CXCR4 and MMP7 expression in some manner, the mechanism underlying such regulation, including the relationship between CD90 and the Wnt/β-catenin pathway, remains to be elucidated.
| CD90 expression in ICC cell lines
| CONCLUSION
Our study indicates that CD90 + ICC cells exhibit increased metastatic potential associated with EMT via activation of Wnt/β-catenin signaling, thus resulting in a greater risk of lymph node metastasis.
